Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.
A new combination therapy offers hope for patients with aggressive B-cell lymphomas who don't respond to standard treatments.
There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). CTIS identifier: 2022-502616-37-00 ; ClinicalTrials.gov identifier: NCT04077723 .
What the study was
- Study design
- Not specified
- Population
- Cancer/disease patients
- Sample size
- 134
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature medicine
Why it surfaced
Matched topic(s): Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Not specified. Published in high-impact journal. Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.